Relationship between plasma high-mobility group box-1 levels and clinical outcomes of ischemic stroke.
High-mobility group box-1 (HMGB1) is regarded as a central mediator of inflammation and involved in many inflammatory diseases. This study aimed to investigate impact of plasma HMGB1 level on 1-year clinical outcomes of ischemic stroke. Plasma HMGB1 levels of 338 patients were quantified by enzyme-linked immunosorbent assay. The end points were mortality and unfavorable outcome (modified Rankin Scale score>2) after 1 year. Plasma HMGB1 level emerged as an independent predictor of 1-year clinical outcomes. Its prognostic value was similar to National Institutes of Health Stroke Scale score's. It improved prognostic value of National Institutes of Health Stroke Scale score. Plasma HMGB1 level represents a novel biomarker for predicting 1-year clinical outcomes of ischemic stroke.